Insulet stock forecast 2027–2029
MyStockButler's October 2026 analysis: Insulet’s weighted forecast points to $162.59 per share in October 2027. It hinges on whether durable Pod use and quality execution convert growth into cash.
Where could Insulet’s shares be by 2029?
Insulet’s weighted forecast points to $162.59 per share in October 2027, a gain of +9%, if new starts become durable Pod use and quality costs stay contained. By October 2029, the forecast reaches $199.83 per share, or +34%.
The forecast assigns 30% probability to the bear case and 50% to the base case. The bull case receives 20%. Retention beyond the first 90 days, repeat Pod orders and remediation progress decide whether the forecast holds. The November 4, 2026 earnings call tests the reduced outlook. The February 2027 call should provide formal 2027 guidance and a revised long-range outlook. Omnipod 6 is targeted for 2027, fully closed-loop type 2 technology for 2028, and the Costa Rica plant for operations in 2029.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 30 % | 107.17 (-28 %) | 103.46 (-31 %) | 98.37 (-34 %) |
| Base | 50 % | 169.57 (+14 %) | 187.96 (+26 %) | 205.03 (+38 %) |
| Bull | 20 % | 228.26 (+53 %) | 288.59 (+94 %) | 339.00 (+128 %) |
| Weighted | 100 % | 162.59 (+9 %) | 182.73 (+23 %) | 199.83 (+34 %) |
What has to go right, and what could go wrong for Insulet?
The base case assumes earnings rise from $538 million to $802 million across the forecast dates. The path starts near the latest six-month net income of $186.1 million and reflects consensus revenue of $3.29 billion for 2026 and $3.73 billion for 2027. The bear case reaches only $540 million as weak type 2 retention slows U.S. growth and correction costs remain consequential. The bull case reaches $928 million as international expansion, repeat refills and operating leverage compound. Management’s guidance for 20%–22% constant-currency revenue growth, 100 basis points of adjusted operating-margin expansion and at least 30% adjusted EPS growth supports the opportunity, but those are adjusted targets rather than net-income guidance.
How much cash does Insulet really make?
A U.S. tax-law change added approximately $70 million to operating and free cash flow in 2025, with little income-statement effect. Stock compensation was $62.7 million in 2025; subtracting it gives an owner-oriented measure of cash after transferring value through shares, not a separate cash payment.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 569.3 | 430.2 | 145.7 | 119.0 | -68.1 |
| − Capital spending | 191.6 | 124.9 | 75.6 | 122.9 | 111.9 |
| = Free cash flow | 377.7 | 305.3 | 70.1 | -3.9 | -180.0 |
| − Stock pay | 62.7 | 69.3 | 48.4 | 40.9 | 34.4 |
| = Real free cash flow | 315.0 | 236.0 | 21.7 | -44.8 | -214.4 |
What does an investor pay for Insulet today?
P/E means the share price divided by earnings per share. Insulet traded at 27.9 times trailing earnings and 19.3 times expected earnings for the next twelve months. At $149.01, those multiples imply earnings per share of about $5.34 and $7.72 respectively. The difference implies roughly 45% higher earnings, but that is arithmetic, not a company forecast.
| Today (Oct 25, 2026) | |
|---|---|
| Share price | 149.01 |
| Market value (calculated) | 10,334.5 |
| Enterprise value (calculated) | 10,748.0 |
| P/E, last 12 months (calculated) | 27.9x |
| P/E, next 12 months (calculated) | 19.3x |
| Free cash flow yield (calculated) | 3.7% |
What this means. The share price is from October 23, not October 25, because that was the latest market closing price.